EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting MCL ‐1 and MAPK overcomes venetoclax resistance in FLT3 ‐ ITD‐ positive AML cells harbouring activating PTPN11 ( SHP ‐2) mutations

Maximilian Fleischmann iD, Ole Hansen, Diana Voigtländer, Julia Bechwar, Lenny-Joseph Schwietzer, Sanja Bahr, Ulf Schnetzke iD, Mike Fischer, Florian H Heidel, Tina M Schnöder, Jörg P Müller, Andreas Hochhaus und 1 weitere

British Journal of Haematology · 2026-03 · 208 (3) · 905-915

DOI: 10.1111/bjh.70344 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, online erschienen am 29.01.2026. Verfasst von Maximilian Fleischmann und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Medical Oncology, Clinic for Internal Medicine II, Comprehensive Cancer Center Central Germany-Campus Jena, University H…. Hauptthemen laut MEDLINE: Myeloid Cell Leukemia Sequence 1 Protein, Sulfonamides, Bridged Bicyclo Compounds, Heterocyclic, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Interdisziplinäres Zentrum für Klinische Forschung, Universitätsklinikum Jena, José Carreras Leukämie-Stiftung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Venetoclax (VEN)‐based therapies have improved the treatment of acute myeloid leukaemia (AML); however, the emergence of resistance remains a major limitation. Mutations in protein tyrosine phosphatase (PTP) non‐receptor type 11 (PTPN11) and FMS like tyrosine kinase 3 with internal tandem duplication (FLT3‐ITD) are common in resistant patients and are linked to activation of mitogen‐activated protein kinase (MAPK) signalling and increased expression of anti‐apoptotic proteins such as myeloid cell leukaemia 1 (MCL‐1) and b‐cell lymphoma‐extra large (BCL(x)L). Murine Ba/F3 cells with different FLT3‐ITD variants were lentiviral transduced to express either wild‐type PTPN11 (Src‐homology 2 containing PTP) or the activating PTPN11‐E76K mutation. Cells were treated with VEN, the MCL‐1 inhibitor S63845 and the mitogen‐activated protein kinase (MEK) inhibitor trametinib (TRA), alone or in combination. Additionally, primary AML samples were examined for drug sensitivity and protein expression profiles. Cells expressing PTPN11‐E76K showed marked resistance to VEN, coinciding with sustained extracellular signal‐regulated kinase activation and elevated MCL‐1 and BCL(x)L levels. Combining VEN with MCL‐1 inhibition significantly increased apoptosis. Co‐treatment with TRA provided substantial synergistic benefits while yielding a more modest benefit in PTPN11‐E76K‐mutant cells. Both PTPN11 and FLT3 mutations confer resistance in AML, making them key factors in identifying high‐risk patients. The presented results highlight the role of MAPK‐driven MCL‐1 and BCL(x)L expression, which mediates VEN resistance. While dual inhibition of B‐cell lymphoma 2 and MCL‐1 is already effective, additional MEK inhibition may further improve outcomes in PTPN11‐mutated AML.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myeloid Cell Leukemia Sequence 1 ProteinSulfonamidesBridged Bicyclo Compounds, HeterocyclicDrug Resistance, NeoplasmLeukemia, Myeloid, Acutefms-Like Tyrosine Kinase 3MutationProtein Tyrosine Phosphatase, Non-Receptor Type 11Antineoplastic AgentsMitogen-Activated Protein KinasesHumansAnimalsMiceCell Line, TumorPyrimidinesThiophenes

Stichwörter der Autor:innen

AMLMAPKMCL‐1resistancevenetoclax

Substanzen

Myeloid Cell Leukemia Sequence 1 ProteinSulfonamidesBridged Bicyclo Compounds, Heterocyclicvenetoclaxfms-Like Tyrosine Kinase 3PTPN11 protein, humanProtein Tyrosine Phosphatase, Non-Receptor Type 11MCL1 protein, humanFLT3 protein, humanS63845

Autor:innen und Institutionen

  • Department of Hematology and Medical Oncology, Clinic for Internal Medicine II, Comprehensive Cancer Center Central Germany-Campus Jena, University Hospital Jena, Jena, Germany.
  • Institute of Human Genetics, University Hospital Jena, Jena, Germany.
  • Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School (MHH), Hannover, Germany.
  • Leibniz Institute on Aging-Fritz-Lipmann-Institute, Jena, Germany.
  • Institute of Molecular Cell Biology, University Hospital Jena, Jena, Germany.

ORCID-Profile: Maximilian Fleischmann, Ulf Schnetzke

Förderung

  • Deutsche Forschungsgemeinschaft
  • Interdisziplinäres Zentrum für Klinische Forschung, Universitätsklinikum Jena
  • José Carreras Leukämie-Stiftung

Zitieren

APA

Fleischmann, M., Hansen, O., Voigtländer, D., Bechwar, J., Schwietzer, L. J., Bahr, S., Schnetzke, U., Fischer, M., Heidel, F. H., Schnöder, T. M., Müller, J. P., Hochhaus, A., & Scholl, S. (2026). Targeting MCL ‐1 and MAPK overcomes venetoclax resistance in FLT3 ‐ ITD‐ positive AML cells harbouring activating PTPN11 ( SHP ‐2) mutations. British Journal of Haematology, 208(3), 905-915. https://doi.org/10.1111/bjh.70344

Vancouver

Fleischmann M, Hansen O, Voigtländer D, Bechwar J, Schwietzer LJ, Bahr S, et al. Targeting MCL ‐1 and MAPK overcomes venetoclax resistance in FLT3 ‐ ITD‐ positive AML cells harbouring activating PTPN11 ( SHP ‐2) mutations. British Journal of Haematology. 2026;208(3):905-915. doi:10.1111/bjh.70344

BibTeX
@article{Fleischmann2026,
  author = {Fleischmann, Maximilian and Hansen, Ole and Voigtländer, Diana and Bechwar, Julia and Schwietzer, Lenny-Joseph and Bahr, Sanja and Schnetzke, Ulf and Fischer, Mike and Heidel, Florian H and Schnöder, Tina M and Müller, Jörg P and Hochhaus, Andreas and Scholl, Sebastian},
  title = {Targeting MCL ‐1 and MAPK overcomes venetoclax resistance in FLT3 ‐ ITD‐ positive AML cells harbouring activating PTPN11 ( SHP ‐2) mutations},
  journal = {British Journal of Haematology},
  year = {2026},
  volume = {208},
  number = {3},
  pages = {905--915},
  doi = {10.1111/bjh.70344}
}
Kostenlos starten →